| Bristol-Myers Squibb SA - Lenalidomid BMS 5 mg, Hartkapseln | | 68490 | | 02 | | Lenalidomid BMS 5 mg | | Hartkapseln | | L04AX04 | | Lenalidomide | | 14.06.2021 | | |
| | Composition | | lenalidomidum 5 mg, lactosum 147 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.4 mg, magnesii stearas, Kapselhülle: gelatina, E 171, Drucktinte: lacca, propylenglycolum, E 172 (nigrum), kalii hydroxidum, pro capsula. | | Packungsbestandteile | | Capsules | | | | | Active Agent | Dose |
|---|
| Lenalidomidum | 5 mg |
| | BAG: Active Agent | Dose |
|---|
| Lenalidomidum | 5 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| (Nigrum) | | | | Carmellosum Natricum Conexum | | | | Cellulosum Microcristallinum | | | | E 171 | | color. | | E 172 | | color. | | Gelatina | | Kapselhülle | | Kalii Hydroxidum | | | | Lacca | | Drucktinte | | Lactosum | 147 mg | | | Magnesii Stearas | | | | Pro Capsula | | | | Propylenglycol | | |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | 21 | 707.76 | 786.15 | A | SL | No |
|
|
